Ensoma is a biotechnology company focused on developing in vivo engineered cellular medicines. The company leverages its proprietary platform to create transformative gene therapies for patients with severe genetic disorders.

Ensoma

Ensoma /en’sōmə/ is derived from the Greek phrase “en soma,” meaning in the body. We develop one-time in vivo treatments that precisely engineer any or all blood and immune cells to cure diseases from within. We have a bigger, bolder vision for genomic medicine: treatments as versatile, precise, and far-reaching as the body’s own cells. Our team takes inspired action towards pushing beyond today’s possible with the goal of delivering a one-time, off-the-shelf treatment to patients everywhere.

RIT Capital Partners

5AM Ventures

Alexandria Venture Investments

Cormorant Asset Management

F-Prime Capital

SymBiosis LLC

Takeda Ventures

Viking Global Investors

Bioluminescence Ventures

Delos Capital

Kite Pharma

Qatar Investment Authority

Catalio Capital Management

Solasta Ventures

Fred Hutchinson

Mirae Asset

COM:ENSOMA

Ensoma

Financials Not Available